Web Focus
Prostate Cancer and Gene Therapy
- Prostate cancer affects one in six men and is the second leading cause of cancer death among men in the United States. In some cases existing treatments for early prostate cancer fail, leading to advanced stage cancer that is merely managed and not cured. Gene therapy shows promise as a treatment strategy that can target both localized and metastasized prostate cancer. Recent clinical trials of various gene therapy strategies have illustrated the safety of these therapies and their potential as an effective treatment option in conjunction with existing cancer therapies. This web focus, presented by Molecular Therapy, highlights some important research that has advanced the field of prostate cancer gene therapy.
: 2007
Advances in Preclinical Investigation of Prostate Cancer Gene Therapy
Marxa L Figueiredo, Chinghai Kao and Lily Wu
Molecular Therapy 15: 1053-1064; doi:10.1038/sj.mt.6300181
Prostate Cancer Gene Therapy Clinical Trials
Svend O Freytag, Hans Stricker, Benjamin Movsas and Jae Ho Kim
Molecular Therapy 15: 1042-1052; 10.1038/sj.mt.6300162
Phase I Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy Combined with IMRT for Prostate Cancer
Svend O Freytag, Benjamin Movsas, Ibrahim Aref, Hans Stricker, James Peabody, Jan Pegg, Yingshu Zhang, Kenneth N Barton, Stephen L Brown, Mei Lu, Adnan Savera and Jae Ho Kim
Molecular Therapy 15: 1016-1023; doi:10.1038/mt.sj.6300120
Five-year Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy for Treatment of Prostate Cancer
Svend O Freytag, Hans Stricker, James Peabody, Jan Pegg, Dell Paielli, Benjamin Movsas, Kenneth N Barton, Stephen L Brown, Mei Lu and Jae Ho Kim
Molecular Therapy 15: 636-642; doi:10.1038/sj.mt.6300068
: 2006
Top of pageA Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer
Eric J. Small, Michael A. Carducci, James M. Burke, Ron Rodriguez, Lawrence Fong, Lynn van Ummersen, D. C. Yu, Junko Aimi, Dale Ando, Peter Working, David Kirn, and George Wilding
Molecular Therapy 14: 107-117; doi:10.1016/j.ymthe.2006.02.011
Second-Generation Replication-Competent Oncolytic Adenovirus Armed with Improved Suicide Genes and ADP Gene Demonstrates Greater Efficacy without Increased Toxicity
Kenneth N. Barton, Dell Paielli, Yingshu Zhang, Sweaty Koul, Stephen L. Brown, Mei Lu, John Seely, Jae Ho Kim and Svend O. Freytag
Molecular Therapy 13: 347-356; doi:10.1016/j.ymthe.2005.10.005
: 2005
Top of pageA Preclinical Large Animal Model of Adenovirus-Mediated Expression of the Sodium-Iodide Symporter for Radioiodide Imaging and Therapy of Locally Recurrent Prostate Cancer
Roisin M. Dwyer, Stephen M. Schatz, Elizabeth R. Bergert, Rae M. Myers, Mary E. Harvey, Kelly L. Classic, Michael C. Blanco, Craig S. Frisk, Ronald J. Marler, Brian J. Davis, Michael K. O'Connor, Stephen J. Russell and John C. Morris
Molecular Therapy 12: 835-841; doi:10.1016/j.ymthe.2005.05.013
: Nature Genetics
Top of pageIntegrative molecular concept modeling of prostate cancer progression
Scott Tomlins et al.
Nature Genetics 39: 41-51; doi:10.1038/ng1935
Multiple prostate cancer risk variants on 8q24
John Witte
Nature Genetics 39: 579-80; doi:10.1038/ng0507-579
: Nature Reviews Genetics
Top of pageEngineering targeted viral vectors for gene therapy
Reinhard Waehler, Stephen J. Russell and David T. Curiel
Nature Reviews Genetics 8: 14-15; doi:10.1038/nrg2141
: Nature Reviews Cancer
Top of pageInflammation in prostate carcinogenesis
Angelo M. De Marzo, Elizabeth A. Platz, Siobhan Sutcliffe, Jianfeng Xu, Henrik Grönberg, Charles G. Drake, Yasutomo Nakai, William B. Isaacs & William G. Nelson
Nature Reviews Cancer 7: 256-269; doi:10.1038/nrc2090
Treating Prostate Cancer: A Rationale for Targeting Local Oestrogens
Stuart J. Ellem and Gail P. Risbridger
Nature Reviews Cancer 7: 621-627; doi:10.1038/nrc2174
: Cancer Gene Therapy
Top of pageEnhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers
S Varghese, S D Rabkin, R Liu, P G Nielsen, T Ipe and R L Martuza
Cancer Gene Therapy 13: 253-265; doi:10.1038/sj.cgt.7700900
Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo
Francesca Wannenes, Silvia Anna Ciafré, Francesco Niola, Gaetano Frajese and Maria Giulia Farace
Cancer Gene Therapy 12: 926-934; doi:10.1038/sj.cgt.7700862
: Gene Therapy
Top of pageCombined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas
S A Kaliberov, L N Kaliberova and D J Buchsbaum
Gene Therapy 12: 407-417; doi:10.1038/sj.gt.3302432
Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases
F Margheri, S D'Alessio, S Serratí , M Pucci, F Annunziato, L Cosmi, F Liotta, R Angeli, A Angelucci, G L Gravina, N Rucci, M Bologna, A Teti, B Monia, G Fibbi and M Del Rosso
Gene Therapy 12: 702-714; doi:10.1038/sj.gt.3302456
: Nature Clinical Practice Oncology
Top of pageDrug Insight: role of the androgen receptor in the development and progression of prostate cancer
Mary-Ellen Taplin
Nature Clinical Practice Oncology 4: 236-244; doi:10.1038/ncponc0765
: Prostate Cancer and Prostatic Diseases
Top of pageWnt signalling and prostate cancer
G W Yardy and S F Brewster
Prostate Cancer and Prostatic Diseases 8: 119-126; doi:10.1038/sj.pcan.4500794
Inhibition of Akt pathways in the treatment of prostate cancer
E C Nelson, C P Evans, P C Mack, R W Devere-White and P N Lara Jr
Prostate Cancer and Prostatic Diseases advance online publication 1 May 2007; doi: 10.1038/sj.pcan.4500974
: Oncogene
Top of pageIdentification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis
K Takayama,K Kaneshiro, S Tsutsumi, K Horie-Inoue, K Ikeda, T Urano, N Ijichi, Y Ouchi, K Shirahige, H Aburatani and S Inoue
Oncogene 26: 4453-4463; doi:10.1038/sj.onc.1210229
